Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ataluren Dystrophin Assessment in nmDMD
NCT03796637Phase 2Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Apr 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ataluren in Duchenne muscular dystrophy (DMD), sponsored by PTC Therapeutics, Inc. Primary endpoint: Mean Dystrophin Levels as Measured by Electrochemiluminescence (ECL) at Day 1. Started Apr 2019; status: completed.
02
Drugs
ataluren
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03796637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03796637.